Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2023 Feb 24;23(1):85.
doi: 10.1186/s12905-022-02118-w.

Comparison of the efficacy of dienogest and GnRH-a after endometriosis surgery

Mingjun Tang #  1 , Wenhui Yang #  1 , Haiyan Zhang  2
Affiliations
Comparative Study

Comparison of the efficacy of dienogest and GnRH-a after endometriosis surgery

Mingjun Tang et al. BMC Womens Health. .

Abstract

Objective: To compare the efficacy of dienogest and GnRH-a after endometriosis surgery.

Methods: Patients with endometriosis who were admitted to our hospital from December 2020 to March 2022 were randomly collected. A total of 81 patients were collected and divided into 40 cases in the control group and 41 cases in the observation group. Among them, the control group was treated with GnRH-a drug, and the observation group was treated with dienogest (DNG).

Results: The study found that the therapeutic effects of the two drugs were basically the same in patients with endometriosis. The VAS and Kupperman scores of the control group were 0.78 ± 0.8, 3.9 ± 1.84, P < 0.05, respectively; the VAS and Kupperman scores of the observation group were 0.73 ± 0.78, 1.55, respectively ± 1.24, P < 0.05, the difference was statistically significant.In the case of postoperative recurrence, the observation group was better than the control group, with 8 cases of recurrence in the control group and 2 cases of recurrence in the observation group, P < 0.05.

Conclusion: In the comparison of postoperative efficacy of the two drugs on patients with endometriosis, dienogest is better than GnRH-a adjuvant drug in postoperative recurrence, and has a good improvement and application, which is worthy of further promotion in clinical practice.

Keywords: Dienogest; Endometriosis; VAS score.

PubMed Disclaimer

Conflict of interest statement

All of the authors had no any personal, financial, commercial, or academic conflicts of interest separately.

References

    1. Choi EJ, Cho SB, Lee SR, et al. Comorbidity of gynecological and non-gynecological diseases with adenomyosis and endometriosis. Obstet Gynecol Sci. 2017;60(6):579–86. doi: 10.5468/ogs.2017.60.6.579. - DOI - PMC - PubMed
    1. Kho PF, Mortlock S, Endometrial Cancer Association Consortium et al. Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Hum Genet. 2021;140(9):1353–65. doi: 10.1007/s00439-021-02312-0. - DOI - PubMed
    1. Alma B, Mdc D, Ag C, et al. Hysterectomy, non-malignant gynecological diseases, and the risk of incident hypertension: the E3N prospective cohort. Maturitas. 2021;150:22–9. doi: 10.1016/j.maturitas.2021.06.001. - DOI - PubMed
    1. Warzecha D, Pietrzak B, Szymusik I, et al. Should the patients with endometriosis be treated as a risk group of pregnancy complications? Single center experience and literature review and literature review. Ginekol Pol. 2020;91(7):383–8. doi: 10.5603/GP.a2020.0084. - DOI - PubMed
    1. Abu JI, Konje JC. Leukotrienes in gynaecology: the hypothetical value of anti-leukotriene therapy in dysmenorrhoea and endometriosis. Hum Reprod Update. 2000;6(2):200–5. doi: 10.1093/humupd/6.2.200. - DOI - PubMed

Publication types

MeSH terms